← Back to headlines
Cantor Fitzgerald Lifts Bristol Myers Price Target Despite Weak Q1 Catalyst
Cantor Fitzgerald has raised its price target for Bristol Myers (BMY), though it notes a weak catalyst for the first quarter.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
